Cargando…

Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor()

BACKGROUND: Preclinical and clinical studies have reported that human epidermal growth factor receptor 2 (HER2) overexpression yields resistance to endocrine therapies. Here the prevalence and prognostic impact of HER2-positive circulating tumor cells (CTCs) were investigated retrospectively in meta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beije, Nick, Onstenk, Wendy, Kraan, Jaco, Sieuwerts, Anieta M., Hamberg, Paul, Dirix, Luc Y., Brouwer, Anja, de Jongh, Felix E., Jager, Agnes, Seynaeve, Caroline M., Van, Ngoc M., Foekens, John A., Martens, John W.M., Sleijfer, Stefan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2016
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071539/ https://www.ncbi.nlm.nih.gov/pubmed/27764697 http://dx.doi.org/10.1016/j.neo.2016.08.007

Ejemplares similares

Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients
por: Beije, Nick, et al.
Publicado: (2017)

An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients
por: Reijm, Esther A., et al.
Publicado: (2016)

Anti-Epithelial Cell Adhesion Molecule Antibodies and the Detection of Circulating Normal-Like Breast Tumor Cells
por: Sieuwerts, Anieta M., et al.
Publicado: (2009)

Molecular characteristics of circulating tumor cells resemble the liver metastasis more closely than the primary tumor in metastatic colorectal cancer
por: Onstenk, Wendy, et al.
Publicado: (2016)

AR splice variants in circulating tumor cells of patients with castration‐resistant prostate cancer: relation with outcome to cabazitaxel
por: Sieuwerts, Anieta M., et al.
Publicado: (2019)

Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel
por: de Kruijff, Ingeborg E., et al.
Publicado: (2019)

Mitochondrial DNA content in breast cancer: Impact on in vitro and in vivo phenotype and patient prognosis
por: Weerts, Marjolein J.A., et al.
Publicado: (2016)

Prospective Evaluation of a Circulating Tumor Cell Sensitivity Profile to Predict Response to Cisplatin Chemotherapy in Metastatic Breast Cancer Patients
por: de Kruijff, I. E., et al.
Publicado: (2021)

High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2− postmenopausal breast cancer patients treated with everolimus and exemestane
por: Kruger, Dinja T., et al.
Publicado: (2020)

Tumor-agnostic ctDNA levels by mFAST-SeqS in first-line HR-positive, HER2 negative metastatic breast cancer patients as a biomarker for survival
por: Verschoor, Noortje, et al.
Publicado: (2023)

Application of circulating tumor DNA in prospective clinical oncology trials – standardization of preanalytical conditions
por: van Dessel, Lisanne F., et al.
Publicado: (2017)

Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer
por: Verschoor, Noortje, et al.
Publicado: (2023)

HER-2 status of circulating tumor cells in a metastatic breast cancer cohort: A comparative study on characterization techniques
por: Brouwer, Anja, et al.
Publicado: (2019)

High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes
por: Riaz, Muhammad, et al.
Publicado: (2012)

DC-SCRIPT is a novel regulator of the tumor suppressor gene CDKN2B and induces cell cycle arrest in ERα-positive breast cancer cells
por: Ansems, Marleen, et al.
Publicado: (2015)

Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer
por: Yu, Jack X, et al.
Publicado: (2007)

Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples – a short report
por: Beije, Nick, et al.
Publicado: (2017)

HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
por: van den Ende, Nadine S., et al.
Publicado: (2022)

Detection of tumor-derived extracellular vesicles in plasma from patients with solid cancer
por: Vitale, Silvia R., et al.
Publicado: (2021)

Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer
por: Bos, M. K., et al.
Publicado: (2023)

Clinical significance of the nuclear receptor co-regulator DC-SCRIPT in breast cancer: an independent retrospective validation study
por: Sieuwerts, Anieta M, et al.
Publicado: (2010)

ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen
por: M. Sieuwerts, Anieta, et al.
Publicado: (2020)

A pipeline for copy number profiling of single circulating tumour cells to assess intrapatient tumour heterogeneity
por: Deger, Teoman, et al.
Publicado: (2022)

Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: a prognosis study
por: Hsieh, Szu-Min, et al.
Publicado: (2009)

Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2− Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2− Breast Cancer
por: Roßwag, Sven, et al.
Publicado: (2021)

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
por: Pinhel, Isabel, et al.
Publicado: (2012)

Association between Acquired Uniparental Disomy and Homozygous Mutations and HER2/ER/PR Status in Breast Cancer
por: Tuna, Musaffe, et al.
Publicado: (2010)

Heritability of Low ER Staining/HER2-Breast Tumors: Are We Missing an Opportunity for Germline Testing?
por: Lovejoy, Leann A., et al.
Publicado: (2020)

Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material
por: Berghuis, A. M. Sofie, et al.
Publicado: (2019)

The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer
por: Vitale, Silvia R., et al.
Publicado: (2022)

Defining the dimensions of circulating tumor cells in a large series of breast, prostate, colon, and bladder cancer patients
por: Mendelaar, Pauline A. J., et al.
Publicado: (2020)

The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer
por: Law, Emily K., et al.
Publicado: (2016)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer
por: Liu, Jingjing, et al.
Publicado: (2016)

SDPS-20 THE HER2 FLIP: HER2 AMPLIFICATION OF TUMOR CELLS IN THE CEREBROSPINAL FLUID (CSF-TCS) OF PATIENTS WITH LEPTOMENINGEAL METASTASIS HAVING SOLID TUMORS; IMPLICATIONS FOR TREATING THE LM TUMOR WITH ANTI-HER2 THERAPY
por: Kumthekar, Priya, et al.
Publicado: (2023)

Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
por: Fehm, Tanja, et al.
Publicado: (2007)

Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor
por: Spector, Neil L., et al.
Publicado: (2015)

EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy
por: Evans, A H, et al.
Publicado: (2010)

Prediction of tumor mutation burden in breast cancer based on the expression of ER, PR, HER-2, and Ki-67
por: Xu, Junnan, et al.
Publicado: (2018)

MRI-Based Radiomics Approach Predicts Tumor Recurrence in ER + /HER2 − Early Breast Cancer Patients
por: Chiacchiaretta, Piero, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tvmgdts7qdh95kkmj8pp10krol